arachidonyltrifluoromethane and Sepsis

Acute respiratory distress syndrome (ARDS) is an acute lung injury of high mortality rate, and sepsis syndrome is one of the most frequent causes of ARDS. Metabolites of arachidonic acid, including thromboxanes and leukotrienes, are proinflammatory mediators and potentially involved in the development of ARDS. A key enzyme for the production of these inflammatory mediators is cytosolic phospholipase A(2) (cPLA(2)). Recently, it has been reported that arachidonyl trifluoromethyl ketone (ATK) is a potent inhibitor of cPLA(2). In the present study, we hypothesized that pharmacological intervention of cPLA(2) could affect acute lung injury. To test this hypothesis, we examined the effects of ATK in a murine model of acute lung injury induced by septic syndrome. The treatment with ATK significantly attenuated lung injury, polymorphonuclear neutrophil sequestration, and deterioration of gas exchange caused by lipopolysaccharide and zymosan administration. The current observations suggest that pharmacological intervention of cPLA(2) could be a novel therapeutic approach to acute lung injury caused by sepsis syndrome.

Topics: Animals; Arachidonic Acids; Bronchoalveolar Lavage Fluid; Cytosol; Enzyme Inhibitors; Leukotriene C4; Leukotriene D4; Leukotriene E4; Lipopolysaccharides; Lung; Male; Mice; Mice, Inbred C57BL; Peroxidase; Phospholipases A; Phospholipases A2; Respiratory Distress Syndrome; Sepsis; Sodium Chloride; Thromboxane B2; Zymosan